- Conditions
- HIV Infections
- Interventions
- Atazanavir+ritonavir, Lopinavir+ritonavir
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 52
- States / cities
- Hobson City, Alabama • Montgomery, Alabama • Phoenix, Arizona + 49 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1321–1344
of 5,305
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Mammography
- Interventions
- Mammography
- Device
- Lead sponsor
- Hologic, Inc.
- Industry
- Eligibility
- 35 Years to 100 Years · Female only
- Enrollment
- 7,500 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2026
- U.S. locations
- 15
- States / cities
- Gilbert, Arizona • Scottsdale, Arizona • Coral Gables, Florida + 11 more
- Conditions
- Metabolism and Nutrition Disorder, Obesity, Obstructive Sleep Apnoea
- Interventions
- liraglutide, placebo
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 359 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 37
- States / cities
- Glendale, California • Oceanside, California • Orange, California + 30 more
- Conditions
- Crohn Disease
- Interventions
- Icotrokinra, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,092 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 64
- States / cities
- Chandler, Arizona • Litchfield Park, Arizona • Scottsdale, Arizona + 51 more
- Conditions
- Breast Cancer, Urothelial Carcinoma
- Interventions
- Trastuzumab deruxtecan, Nivolumab
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 10
- States / cities
- Santa Monica, California • New Haven, Connecticut • Miami, Florida + 7 more
- Conditions
- Keratoconjunctivitis Sicca
- Interventions
- 1% Tavilermide Ophthalmic Solution, Placebo Ophthalmic Solution
- Drug
- Lead sponsor
- Mimetogen Pharmaceuticals USA, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 429 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 2
- States / cities
- Louisville, Kentucky • Nashville, Tennessee
- Conditions
- Irritability Associated With Autism Spectrum Disorder
- Interventions
- KarXT, KarX-EC, KarXT + KarX-EC Matching Placebo
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 5 Years to 17 Years
- Enrollment
- 176 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 29
- States / cities
- Dothan, Alabama • Phoenix, Arizona • Anaheim, California + 25 more
- Conditions
- Advanced Solid Tumors, Colorectal Cancer
- Interventions
- VVD-133214, Pembrolizumab, Bevacizumab
- Drug
- Lead sponsor
- Vividion Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 18
- States / cities
- Tucson, Arizona • Duarte, California • Irvine, California + 14 more
- Conditions
- Advanced Breast Cancer, Breast Cancer
- Interventions
- Neratinib, Lapatinib, Capecitabine
- Drug
- Lead sponsor
- Puma Biotechnology, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 233 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2018
- U.S. locations
- 44
- States / cities
- Tucson, Arizona • Murrieta, California • Orange, California + 40 more
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Interventions
- Ubamatamab, Bevacizumab, Cemiplimab, Fianlimab, PLD, Sarilumab, REGN10597
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 297 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • La Jolla, California • Los Angeles, California + 17 more
- Conditions
- Growth Hormone Deficiency
- Interventions
- No intervention
- Other
- Lead sponsor
- Ascendis Pharma Endocrinology Division A/S
- Industry
- Eligibility
- Not listed
- Enrollment
- 900 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2033
- U.S. locations
- 27
- States / cities
- Phoenix, Arizona • Orange, California • Sacramento, California + 23 more
- Conditions
- Plaque Psoriasis
- Interventions
- M518101, placebo, Dovonex
- Drug
- Lead sponsor
- Maruho Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 294 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2011
- U.S. locations
- 32
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Fresno, California + 28 more
- Conditions
- Myocardial Injury
- Interventions
- CCTA scan
- Radiation
- Lead sponsor
- University of Louisville
- Other
- Eligibility
- 18 Years to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky
- Conditions
- Atopic Dermatitis
- Interventions
- Crisaborole ointment 2%
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 3 Months to 23 Months
- Enrollment
- 137 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 23
- States / cities
- Hot Springs, Arkansas • San Diego, California • San Francisco, California + 17 more
- Conditions
- Hypertriglyceridemia, Atherosclerotic Cardiovascular Disease, Severe Hypertriglyceridemia
- Interventions
- Olezarsen, Placebo
- Drug
- Lead sponsor
- Ionis Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 154 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 21
- States / cities
- Lincoln, California • Montclair, California • Boca Raton, Florida + 17 more
- Conditions
- Advanced Solid Tumors
- Interventions
- ASP1948, nivolumab, pembrolizumab
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 190 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 17
- States / cities
- New Haven, Connecticut • Louisville, Kentucky • Baltimore, Maryland + 13 more
- Conditions
- Clinical Efficacy
- Interventions
- PTFE membrane, Collagen membrane
- Procedure
- Lead sponsor
- University of Louisville
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Louisvile, Kentucky
- Conditions
- Alcoholic Hepatitis
- Interventions
- Not listed
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 1,133 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2024
- U.S. locations
- 9
- States / cities
- Indianapolis, Indiana • Louisville, Kentucky • Boston, Massachusetts + 6 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- iloprost
- Drug
- Lead sponsor
- Actelion
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 32
- States / cities
- La Jolla, California • Sacramento, California • Torrance, California + 28 more
- Conditions
- Air Pollution Toxicity
- Interventions
- L-carnosine, placebo
- Dietary Supplement · Other
- Lead sponsor
- University of Louisville
- Other
- Eligibility
- 22 Years to 65 Years
- Enrollment
- 299 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky
- Conditions
- Solid Tumor, Solid Tumor, Adult, Advanced Solid Tumor, Metastatic Tumor, Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Metastatic Ovarian Carcinoma, Endometrial Cancer, Endometrial Neoplasms, Endometrial Diseases, Metastatic Endometrial Cancer, Metastatic Endometrial Carcinoma, Advanced Endometrial Carcinoma, Advanced Ovarian Carcinoma, Gastric Cancer, Advanced Gastric Carcinoma, Metastatic Gastric Cancer, Metastatic Gastric Carcinoma, Small-cell Lung Cancer, Small Cell Lung Carcinoma, Triple Negative Breast Cancer, Triple Negative Breast Neoplasms, Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Carcinoma, CCNE1 Amplification, Hormone Receptor Negative Breast Carcinoma, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Progesterone-receptor-positive Breast Cancer
- Interventions
- NKT3447
- Drug
- Lead sponsor
- NiKang Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 8
- States / cities
- San Francisco, California • Denver, Colorado • Celebration, Florida + 5 more
- Conditions
- Moderate to Severe Palmoplantar Psoriasis
- Interventions
- secukinumab 150 mg, secukinumab 300 mg, Placebo
- Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 205 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Indianapolis, Indiana + 5 more
- Conditions
- Ulcerative Colitis
- Interventions
- abatacept (ABA), placebo, abatacept
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 591 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 50
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 43 more
- Conditions
- Obesity
- Interventions
- NNC0519-0130, Placebo, Tirzepatide
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 354 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 49
- States / cities
- Mesa, Arizona • Little Rock, Arkansas • Searcy, Arkansas + 40 more